Phaseline

Targets › MAT2A

MAT2A (S-adenosylmethionine synthase isoform type-2): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Jan 2027.

Catalyzes the formation of S-adenosylmethionine from methionine and ATP. The reaction comprises two steps that are both catalyzed by the same enzyme: formation of S-adenosylmethionine (AdoMet) and triphosphate, and subsequent hydrolysis of the triphosphate. (UniProt, P31153)

Open in Phaseline: the race on MAT2A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
IDEAYA BiosciencesIDE397
MAT2A inhibitor
MAT2APhase 1Solid Tumor; NSCLC AdenocarcinomaJan 2027
Servier Bio-InnovationS095035
MAT2A inhibitor
MAT2APhase 1MTAP-deleted Solid TumorsMay 2027

Conditions

Solid Tumor (1) NSCLC Adenocarcinoma (1) MTAP-deleted Solid Tumors (1)

Modalities

mixed (1), small molecule (1)

Companies

IDEAYA Biosciences (1) Servier Bio-Innovation (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.